NCT05010863Recruiting
Gastric Cancer Marker Detection and Its Kit Development
Source: ClinicalTrials.gov · Last updated 18 Aug 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The gastric cancer diagnosis and treatment specifications clearly point out that tumor markers need to be detected in the process of diagnosis, efficacy evaluation and follow-up. However, there is currently a lack of gastric cancer markers with high sensitivity and specificity, and the detection of markers is limited to a single index analysis, which has many shortcomings such as long analysis time, large reagent consumption, and high detection cost. Therefore, this project will use protein chips to detect new types of gastric cancer patient markers and establish a multi-diagnostic model for early screening of gastric cancer. Finally, monoclonal antibodies will be produced against various high-specific tumor markers and a gastric cancer diagnostic kit will be established.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 530 (estimated)
- First submitted
- 11 Aug 2021
- Start date
- 1 Jan 2021
- Primary completion date
- 30 Dec 2023
- Lead sponsor
- Second Affiliated Hospital of Wenzhou Medical University
- NCT number
- NCT05010863
What you commit to
- Study type: Observational
- Planned participants: 530
- From 1 Jan 2021 to the primary completion date, 30 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received anti-tumor treatments such as surgery, chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy, biological therapy or Chinese medicines with anti-cancer and anti-tumor effects in the instructions;
- Participated in any clinical trial within 90 days before the experiment;
- Received major surgery within 90 days before the experiment;
- Received bone marrow transplantation 90 days before the experiment;
Other illness
- Those who have a history of other tumors, autoimmune diseases and allergies;
Other
- The tumor foci cannot be clearly derived from a specific tumor type;
- Subjects who may not be able to complete the study due to other reasons or who are determined by the investigator to be unsuitable to participate in this study.
Who the study is looking for
- patient
- Age is greater than or equal to 18 years old (including 18 years old);
- Patients who are diagnosed with cancer after pathological diagnosis;
- Can provide enough tissue samples;
- Have not received anti-tumor treatment in the past;
- Comply with the principle of informed consent and sign the informed consent form.
- healthy person:
- Age is greater than or equal to 18 years old (including 18 years old);
- No underlying disease;
- Can provide enough tissue samples;
- Comply with the principle of informed consent and sign the informed consent form.
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| No. 109, Xueyuan West Road, Lucheng District, Wenzhou City，Zhejiang provincece Coordinator of this site? Confirm its status | Wenzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.